Susan X Zhao1, Calvin Kwong2, Aravind Swaminathan3, Amit Gohil4, Michael H Crawford5. 1. Division of Cardiology, Santa Clara Valley Medical Center, San Jose, California. Electronic address: susanxzhao@gmail.com. 2. Department of Medicine, Santa Clara Valley Medical Center, San Jose, California. 3. Division of Cardiology, Santa Clara Valley Medical Center, San Jose, California. 4. Division of Pulmonary and Critical Care Medicine, Santa Clara Valley Medical Center, San Jose, California. 5. Division of Cardiology, University of California-San Francisco, San Francisco, California.
Abstract
OBJECTIVES: This study sought to characterize patients with methamphetamine-associated pulmonary arterial hypertension (MA-PAH) and cardiomyopathy (MA-CMP), to compare with MA controls (MA-CTL), users with structurally normal hearts, with the aim of identifying risk factors for these conditions. BACKGROUND: MA-PAH and MA-CMP are 2 poorly understood cardiac complications in MA users. METHODS: We retrospectively studied the clinical characteristics and outcomes of 50 MA-PAH, 296 MA-CMP, and 356 MA-CTL patients, whom we evaluated between 2010 and 2017. RESULTS: After a median follow-up of 20.0 months (interquartile range [IQR]: 7.6 to 42.6 months), all-cause mortality was 18.0% for MA-PAH, 15.2% for MA-CMP, and 4.5% for MA-CTL group (p < 0.001). More women (58%) were in the MA-PAH group than in the MA-CMP (14%; p < 0.001) and MA-CTL (42%; p = 0.028) groups, whereas the MA-CMP group was predominantly male (86% vs. 58% in the MA-CTL group; p < 0.001). More MA-CMP patients had hypertension (p < 0.001) or alcoholism (p < 0.001) than MA-CTL patients. Logistic regression analyses identified male sex, alcoholism, and hypertension as independent factors associated with MA-CMP with the following respective adjusted odds ratios (OR) of 3.791 (95% confidence interval [CI]: 2.508 to 5.730), OR of 2.959 (95% CI: 2.084 to 4.203), and OR of 2.111 (95% CI: 1.486 to 2.999), whereas female sex was the only factor associated with MA-PAH. CONCLUSIONS: Both MA-PAH and MA-CMP patients carried significant disease burden and mortality risk. Male sex, hypertension, and alcoholism were strongly associated with MA-CMP, whereas female sex and other unknown factors may influence development of MA-PAH. This study adds to the understanding of MA-associated cardiac complications and highlights directions for future investigation. Published by Elsevier Inc.
OBJECTIVES: This study sought to characterize patients with methamphetamine-associated pulmonary arterial hypertension (MA-PAH) and cardiomyopathy (MA-CMP), to compare with MA controls (MA-CTL), users with structurally normal hearts, with the aim of identifying risk factors for these conditions. BACKGROUND: MA-PAH and MA-CMP are 2 poorly understood cardiac complications in MA users. METHODS: We retrospectively studied the clinical characteristics and outcomes of 50 MA-PAH, 296 MA-CMP, and 356 MA-CTL patients, whom we evaluated between 2010 and 2017. RESULTS: After a median follow-up of 20.0 months (interquartile range [IQR]: 7.6 to 42.6 months), all-cause mortality was 18.0% for MA-PAH, 15.2% for MA-CMP, and 4.5% for MA-CTL group (p < 0.001). More women (58%) were in the MA-PAH group than in the MA-CMP (14%; p < 0.001) and MA-CTL (42%; p = 0.028) groups, whereas the MA-CMP group was predominantly male (86% vs. 58% in the MA-CTL group; p < 0.001). More MA-CMPpatients had hypertension (p < 0.001) or alcoholism (p < 0.001) than MA-CTL patients. Logistic regression analyses identified male sex, alcoholism, and hypertension as independent factors associated with MA-CMP with the following respective adjusted odds ratios (OR) of 3.791 (95% confidence interval [CI]: 2.508 to 5.730), OR of 2.959 (95% CI: 2.084 to 4.203), and OR of 2.111 (95% CI: 1.486 to 2.999), whereas female sex was the only factor associated with MA-PAH. CONCLUSIONS: Both MA-PAH and MA-CMPpatients carried significant disease burden and mortality risk. Male sex, hypertension, and alcoholism were strongly associated with MA-CMP, whereas female sex and other unknown factors may influence development of MA-PAH. This study adds to the understanding of MA-associated cardiac complications and highlights directions for future investigation. Published by Elsevier Inc.
Authors: Christopher G Kevil; Nicholas E Goeders; Matthew D Woolard; Md Shenuarin Bhuiyan; Paari Dominic; Gopi K Kolluru; Connie L Arnold; James G Traylor; A Wayne Orr Journal: Arterioscler Thromb Vasc Biol Date: 2019-08-21 Impact factor: 8.311
Authors: Paari Dominic; Javaria Ahmad; Hajra Awwab; Md Shenuarin Bhuiyan; Christopher G Kevil; Nicholas E Goeders; Kevin S Murnane; James C Patterson; Kristin E Sandau; Rakesh Gopinathannair; Brian Olshansky Journal: Circ Arrhythm Electrophysiol Date: 2021-12-28
Authors: Nicholas A Kolaitis; Roham T Zamanian; Vinicio A de Jesus Perez; David B Badesch; Raymond L Benza; Charles D Burger; Murali M Chakinala; Jean M Elwing; Jeremy Feldman; Matthew R Lammi; Stephen C Mathai; John W McConnell; Kenneth W Presberg; Jeffrey C Robinson; Jeffrey Sager; Oksana A Shlobin; Marc A Simon; Steven M Kawut; David V Glidden; Jonathan P Singer; Teresa De Marco Journal: Ann Am Thorac Soc Date: 2021-04
Authors: Yangyang Cheng; Chi-Kwong Tung; Albert Kar Kin Chung; Wan-Wan Liu; Duo Huang; Pak Hei Chan; Ming Lam; Wai-Chi Chan; Chung-Wah Siu; Jo Jo Hai Journal: BMJ Open Date: 2019-08-01 Impact factor: 2.692
Authors: Harpreet Singh Bhatia; Marin Nishimura; Stephen Dickson; Eric Adler; Barry Greenberg; Isac C Thomas Journal: Heart Date: 2020-10-05 Impact factor: 5.994